Engineering Clinically Relevant Probiotics with Switchable “Nano‐Promoter” and “Nano‐Effector” for Precision Tumor Therapy

Probiotics have the potential as biotherapeutic agents for cancer management in preclinical models and human trials by secreting antineoplastic or immunoregulatory agents in the tumor microenvironment (TME). However, current probiotics lack the ability to dynamically respond to unique TME characteri...

Full description

Saved in:
Bibliographic Details
Published in:Advanced materials (Weinheim) 2024-02, Vol.36 (5), p.e2304257-n/a
Main Authors: Cao, Fangfang, Jin, Lulu, Zhang, Chenyin, Gao, Yong, Qian, Zhefeng, Wen, Hongyang, Yang, Sisi, Ye, Ziqiang, Hong, Liangjie, Yang, Huang, Tong, Zongrui, Cheng, Liang, Ding, Yuan, Wang, Weilin, Yu, Guocan, Mao, Zhengwei, Chen, Xiaoyuan
Format: Article
Language:English
Subjects:
Acidification
Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
artificial enzymes
Cancer
colorectal cancer
Controllability
Humans
metabolic regulation
Metabolites
nano‐effectors
nano‐promoter
Neoplasms - therapy
Peroxidase
Probiotics
Probiotics - therapeutic use
Reactive Oxygen Species
Tumor Microenvironment
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!